NCT03295396 2025-07-28ONC201 in Adults With Recurrent H3 K27M-mutant GliomaJazz PharmaceuticalsPhase 2 Terminated73 enrolled 13 charts 1 FDA
NCT03416530 2025-02-14ONC201 in Pediatric H3 K27M GliomasJazz PharmaceuticalsPhase 1 Terminated134 enrolled 1 FDA
NCT03134131 2022-03-14Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade GliomasJazz PharmaceuticalsNo longer available1 FDA